Leuprorelin: Subcutaneous depot formulation (Eligard®) for advanced prostate cancer

American Journal of Cancer

Volumn 3, Issue 3, 2004, Pages 197-201

  Evans, Hannah C ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; LEUPRORELIN; POLYMER; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; BONE PAIN; BREAST HYPERTROPHY; BREAST TENDERNESS; BURNING SENSATION; CANCER PALLIATIVE THERAPY; CAPILLARY RESISTANCE; CASTRATION; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; ERYTHEMA; GYNECOMASTIA; HORMONE RELEASE; HOT FLUSH; HUMAN; INJECTION PAIN; INJECTION SITE; LIBIDO DISORDER; MALAISE; NAUSEA; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; TESTIS ATROPHY; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; URINARY DYSFUNCTION;

EID: 4544234251     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200403030-00008     Document Type: Review

References (21)

1. American Cancer Society. Cancer facts and figures 2004 [online]. Available from URL: http://www.cancer.org [Accessed 2004 Feb 23]
2. National Comprehensive Cancer Network. Prostate cancer: treatment guidelines for patients [online]. Available from URL: http://www.nccn.org [Accessed 2004 Feb 23]
3. Naughton M, Picus J. Advanced prostate cancer: a state-of-the-art guide to pharmacological management. Am J Cancer 2002; 1 (1): 13-22
4. Anonymous. Androgen deprivation is the mainstay of treatment for advanced prostate cancer. Drug Ther Perspect 2003 Mar; 19 (3): 16-9
5. Chrisp P, Sorkin EM. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging 1991 Nov; 1 (6): 487-509
6. Plosker GL, Brogden RN. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 1994; 48 (6): 930-67
7. Croom KF, Perry CM. Leuprolide acetate: once-yearly subcutaneous implant in advanced prostate cancer. American Journal of Cancer 2003; 2 (1): 57-64
8. Sanofi-Synthelabo Inc. Eligard® 7.5 mg (leuprolide acetate for injectable suspension): prescribing information [online]. Available from URL: http://www.sanofi-synthelabous.com [Accessed 2004 Feb 28]
9. Sanofi-Synthelabo Inc. Eligard® 22.5 mg (leuprolide acetate for injectable suspension): prescribing information [online]. Available from URL: http://www.sanofi-synthelabous.com [Accessed 2004 Feb 28]
10. Sanofi-Synthelabo Inc. Eligard® 30 mg (leuprolide acetate for injectable suspension): prescribing information [online]. Available from URL: http://www.sanofi-synthelabous.com [Accessed 2004 Feb 28]
11. Conn PM, Crowley WF. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991; 324 (2): 93-103
12. Eisenberger MA, O'Dwyer PJ, Friedman MA. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol 1986; 4 (3): 414-24
13. Swanson LJ, Seely JH, Garnick MB. Gonadotropin-releasing hormone analogs and prostatic cancer. Crit Rev Oncol Hematol 1988; 8 (1): 1-26
14. Perez-Marreno R, Chu FM, Gleason D, et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002 Nov; 24 (11): 1902-14
15. Chu FM, Jayson M, Dineen MK, et al. A clinical study of 22.5 mg. LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002 Sep; 168: 1199-203
16. Sartor O, Dineen MK, Perez-Marreno R, et al. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer. Urology 2003 Aug; 62 (2): 319-23
17. Santen RJ, Demers LM, Max DT, et al. Long term effects of administration of a gondaotropin-releasing hormone superagonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab 1984; 58 (2): 397-400
18. Glode LM, Smith Jr JA, Leuprolide Study Group. Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide. J Urol 1987 Jan; 137: 57-60
19. Rajfer J, Swerdloff RS, Heber DM. Testicular histology following chronic gonadotropin-releasing hormone agonist treatment. Fertil Steril 1984; 42 (5): 765-71
20. Smith Jr JA, Urry RL. Testicular histology after prolonged treatment with a gonadotropin-releasing hormone analogue. J Urol 1985 Apr; 133: 612-4
21. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86 (6): 2787-91